SOFIE granted IND for 18F-FAPI in Phase 2 study

Dulles, VA – November 29, 2022 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]

2025-10-15T16:42:14+00:0029, Nov 2022|News|

Initial Results of FAPI-PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer

Philipp Backhaus 1Matthias C Burg 2

2025-10-13T13:39:20+00:0017, Nov 2022|Publications|

3-time-point PET-analysis of FAPI-46 in a variety of cancers

Mahnoosh Naeimi 1Peter L Choyke 2

2025-10-13T13:39:26+00:0010, Nov 2022|Publications|

FAPI Clinical Development Updates

Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
ICPO Theranostics FAP Summit (virtual)
November 5, 2022 […]

2025-11-03T16:09:10+00:005, Nov 2022|Presentations|

Focus on FAPI Newsletter – Q4 2022

A WORD FROM OUR CHIEF SCIENTIFIC OFFICER

We are excited to launch our FAPI newsletter […]

2025-12-03T20:02:45+00:0031, Oct 2022|Newsletter|

SOFIE submits IND for [18F]-FAPI-74 in Phase 2 study of Gastrointestinal Cancers

Dulles, VA – October 31, 2022 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]

2025-10-15T16:42:15+00:0031, Oct 2022|News|

First Patient Imaged in SOFIE’s FAPI Phase II Trial

SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged […]

2025-10-15T16:42:15+00:0013, Oct 2022|News|

Monitoring Therapeutic Response to Anti-Fibroblast Activation Protein (FAP) CAR T Cells using [18F]AlF-FAPI-74

Iris K Lee, Estela Noguera-Ortega, Zebin Xiao, Leslie Todd, John Scholler, Decheng Song, Maria Liousia, […]

2025-10-13T13:39:56+00:0018, Aug 2022|Publications|

Automated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types

Ammar Alfteimi, Ulf Lützen, Alexander Helm, Michael Jüptner, Marlies Marx, Yi Zhao, Maaz Zuhayra

Abstract

2025-10-15T16:40:44+00:0029, Jul 2022|Publications|

Current Status of Clinical Trials on FAP Targeted Radiopharmaceuticals

Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
Gordon Research Conference-Radionuclide Theranostics for the Management […]

2025-11-03T16:09:18+00:0019, Jul 2022|Presentations|
Go to Top